Tag Archives: DLBCL

July, 2018

11 July
Imbruvica Fails to Meet Primary Endpoint in Phase 3 Trial in Newly Diagnosed Non-Germinal Center B Cell Subtype of DLBCL

RARITAN, N.J., July 11, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today topline results from the Phase 3 PHOENIX trial evaluating the investigational use of IMBRUVICA® (ibrutinib) in the treatment of newly diagnosed non-Germinal Center B cell (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL), …
Share

18 January
Kite and Pfizer Collaborate to Evaluate Yescarta and Utomilumab in Large B-Cell Lymphoma

FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), announced it has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta™ (axicabtagene ciloleucel) and Pfizer’s utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in …
Share
17 January
FDA Grants Priority Review to Novartis’ Kymriah for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Basel, January 17, 2018 – Novartis today announced that its supplemental Biologics License Application (sBLA) for KymriahTM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for or relapse after autologous stem cell transplant (ASCT) has …
Share

19 October
FDA Approves Kite’s CAR-T Therapy Yescarta for the Treatment of Large B-Cell Lymphoma

FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or …
Share
6 October
Researchers Identify Genetic Drivers of Most Common Form of Lymphoma

DURHAM, N.C. — Lymphoma is the most common blood cancer, but the diagnosis belies a wildly diverse and little understood genetic foundation for the disease that hampers successful treatment. An international research effort led by Duke Cancer Institute scientists has been working to better understand the genetic underpinnings of the …
Share

3 August
Kite Announces Publication of Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma Outcomes

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD. The study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), showed outcomes in patients with refractory aggressive …
Share

20 July
Kite’s CAR-T Cell Therapy Demonstrates Positive Results in Patients with Chemorefractory Aggressive NHL

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, highlighted the recent online publication of results in Molecular Therapy from a National Cancer Institute (NCI) study of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive NHL including diffuse large B-cell lymphoma (DLBCL). The research, led by James …
Share

23 June
Genentech’s Rituxan Hycela Receives FDA Approval for Treatment of Certain Blood Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or …
Share
8 June
Interim Results Show Novartis’ CAR-T Drug Induces Durable Response in Lymphoma Patients

Basel, June 7, 2017 – Novartis announced findings from an interim analysis of its multi-center Phase II JULIET study (NCT02445248) of CTL019 (tisagenlecleucel) in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL), which will be presented at the International Conference on Malignant Lymphoma (ICML) meeting, Lugano, …
Share

18 April
Novartis’ CAR-T Therapy Receives Breakthrough Therapy Designation for Diffuse Large B-Cell Lymphoma

Basel, April 18, 2017 – Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have …
Share

Page 1 of 212 »